Sorafenib and sunitinib: A dermatologist's perspective

Sorafenib and sunitinib are inhibitors of tumor angiogenesis have recently generated curiosity regarding its role in cutaneous toxicities, which has severely affected the daily activities resulting in interruption or dose modification of therapy in renal cell carcinoma and hepatocellular carcinomas....

Descripción completa

Detalles Bibliográficos
Autores principales: Pragasam, Vijendran, Verma, Rajesh, Vasudevan, Biju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Guest Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937473/
https://www.ncbi.nlm.nih.gov/pubmed/24616845
http://dx.doi.org/10.4103/2229-5178.126017
_version_ 1782305500510027776
author Pragasam, Vijendran
Verma, Rajesh
Vasudevan, Biju
author_facet Pragasam, Vijendran
Verma, Rajesh
Vasudevan, Biju
author_sort Pragasam, Vijendran
collection PubMed
description Sorafenib and sunitinib are inhibitors of tumor angiogenesis have recently generated curiosity regarding its role in cutaneous toxicities, which has severely affected the daily activities resulting in interruption or dose modification of therapy in renal cell carcinoma and hepatocellular carcinomas. We discuss the pathophysiology, adverse cutaneous effects and their grading, potential high risk factors, role of gene polymorphism, critical period of hand-foot skin reaction development and their management.
format Online
Article
Text
id pubmed-3937473
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-39374732014-03-10 Sorafenib and sunitinib: A dermatologist's perspective Pragasam, Vijendran Verma, Rajesh Vasudevan, Biju Indian Dermatol Online J Guest Editorial Sorafenib and sunitinib are inhibitors of tumor angiogenesis have recently generated curiosity regarding its role in cutaneous toxicities, which has severely affected the daily activities resulting in interruption or dose modification of therapy in renal cell carcinoma and hepatocellular carcinomas. We discuss the pathophysiology, adverse cutaneous effects and their grading, potential high risk factors, role of gene polymorphism, critical period of hand-foot skin reaction development and their management. Medknow Publications & Media Pvt Ltd 2014 /pmc/articles/PMC3937473/ /pubmed/24616845 http://dx.doi.org/10.4103/2229-5178.126017 Text en Copyright: © Indian Dermatology Online Journal http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Guest Editorial
Pragasam, Vijendran
Verma, Rajesh
Vasudevan, Biju
Sorafenib and sunitinib: A dermatologist's perspective
title Sorafenib and sunitinib: A dermatologist's perspective
title_full Sorafenib and sunitinib: A dermatologist's perspective
title_fullStr Sorafenib and sunitinib: A dermatologist's perspective
title_full_unstemmed Sorafenib and sunitinib: A dermatologist's perspective
title_short Sorafenib and sunitinib: A dermatologist's perspective
title_sort sorafenib and sunitinib: a dermatologist's perspective
topic Guest Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937473/
https://www.ncbi.nlm.nih.gov/pubmed/24616845
http://dx.doi.org/10.4103/2229-5178.126017
work_keys_str_mv AT pragasamvijendran sorafenibandsunitinibadermatologistsperspective
AT vermarajesh sorafenibandsunitinibadermatologistsperspective
AT vasudevanbiju sorafenibandsunitinibadermatologistsperspective

Ejemplares similares